FierceBiotech (@FierceBiotech) header
FierceBiotech (@FierceBiotech) profile picture

The dominant B2B news brand for biotech. Delivering news, revealing insights straight to your inbox.

Washington, DC
Joined December 2008
Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)Photo by FierceBiotech (@FierceBiotech)
Pfizer is entering the in vivo CAR-T race with a deal worth up to $2.6 billion for three preclinical autoimmune programs from China’s Starna Therapeutics, including $330 million upfront. fiercebiotech.com/biotech/pf…
4
2
9
2,559
Regeneron's baloncibart met the primary endpoint in a phase 2 trial for POTS, a disorder with no FDA-approved treatments. The company now plans to launch a potentially pivotal study in 2027. fiercebiotech.com/biotech/re…
1
8
23
4,372
Cellectis plans to cut up to 70% of its workforce through 2027 as the biotech shifts away from allogeneic CAR-T therapies to focus on in vivo gene editing. fiercebiotech.com/biotech/ce…
2
1
3,054
MetaVia's GLP-1/glucagon drug reduced liver fat and body weight in a phase 1 trial, but questions remain about its competitive edge. The biotech is now targeting a less crowded corner of the liver disease market. fiercebiotech.com/biotech/me…
2
8
3,834
Evommune is joining Novartis in the race to develop VAV1-targeting molecular glue degraders, striking a deal worth up to $1.1 billion with China's Hinova Pharmaceuticals. fiercebiotech.com/biotech/ev…
1
1
18
3,522
Just two months after launching a phase 1 trial, Sanofi is pulling the plug on a STAT6 degrader licensed from Nurix. The decision comes amid a broader pipeline shake-up under Sanofi's new CEO. fiercebiotech.com/biotech/sa…
4
1
1
18
5,671
Boehringer Ingelheim is doubling down on Chinese biotech innovation, striking a deal worth up to $7.4 billion with Sino Biopharmaceutical for six preclinical cancer programs spanning ADCs and T-cell engagers. fiercebiotech.com/biotech/bo…
1
2
23
3,605
FierceBiotech retweeted
Enhertu has transformed HER2 breast cancer treatment and set a high bar for the next generation of drugs. Now, the race is on to develop something even better, but finding a worthy successor is proving to be easier said than done. fiercebiotech.com/biotech/ad…
2
4
16
3,428